Analysts fell to the sidelines weighing in on Galapagos (GLPG) and Mesoblast (MESO) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
In a report issued on December 17, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos, with a price target of $90.00. The company’s shares closed last Monday at $96.85, close to its 52-week low of $93.01.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 10.4% and a 52.2% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
Galapagos has an analyst consensus of Hold, with a price target consensus of $128.12, which is a 34.5% upside from current levels. In a report issued on December 10, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
In a report issued on December 18, Kennen MacKay from RBC Capital maintained a Hold rating on Mesoblast, with a price target of $6.00. The company’s shares closed last Monday at $8.59.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 13.4% and a 56.7% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, BioMarin Pharmaceutical, and Seattle Genetics.
Currently, the analyst consensus on Mesoblast is a Moderate Buy with an average price target of $13.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.